AstraZeneca Expects Phase III Zactima Data For NSCLC In 2008
Company completes enrollment in ZEST trial evaluating the oral anti-cancer drug vandetanib compared to Tarceva.
Company completes enrollment in ZEST trial evaluating the oral anti-cancer drug vandetanib compared to Tarceva.